Heart Rate Control as an Additional Therapeutic Strategy in Patients With Decompensated Heart Failure: a Prospective, Randomized, Double-blinded, Placebo-controlled Study.
Phase of Trial: Phase I/II
Latest Information Update: 07 Dec 2018
Price : $35 *
At a glance
- Drugs Ivabradine (Primary)
- Indications Decompensated heart failure
- Focus Therapeutic Use
- Acronyms CONSTATHE
- 01 Nov 2016 Planned End Date changed from 1 Nov 2015 to 1 Aug 2017.
- 01 Nov 2016 Planned primary completion date changed from 1 May 2015 to 1 Jan 2017.
- 18 Sep 2014 New trial record